Falcon Point Capital’s Antares Pharma, Inc. ATRS Stock Holding History

Falcon Point Capital’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-130,200	Closed	-$354K	–	113
2018 Q4	$354K	Sell	130,200 -77,247	-37%	-$254K	0.21%	74
2018 Q3	$697K	Sell	207,447 -15,054	-7%	-$46.5K	0.15%	66
2018 Q2	$574K	Hold	222,501	–	–	0.11%	94
2018 Q1	$490K	Buy	+222,501	New	+$501K	0.1%	94

Other funds holding ATRS

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Falcon Point Capital's ATRS Position: Q1 2019 in Review

Falcon Point Capital sold out of Antares Pharma, Inc. (ATRS) in Q1 2019, closing a stake of 130,200 shares — an estimated $354K sold.

Falcon Point Capital first reported a position in ATRS in Q1 2018 and held it in 4 quarters. The position peaked at $697K in Q3 2018. 132 funds tracked by Wall St. Rank hold ATRS as of Q1 2019.

Falcon Point Capital reported no remaining Antares Pharma, Inc. position as of Q1 2019 after selling out during the quarter.
Falcon Point Capital sold 130,200 Antares Pharma, Inc. shares in Q1 2019, an estimated $354K.
Falcon Point Capital first reported a position in Antares Pharma, Inc. in Q1 2018 and held it in 4 quarters.
Falcon Point Capital's Antares Pharma, Inc. position peaked at $697K in Q3 2018.
132 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q1 2019.

Based on Falcon Point Capital's 13F filing for Q1 2019, filed 8 May 2019.